http://www.reportlinker.com/ci02235/Biopharmaceutical.html Thu, 23 May 2013 16:13:25 +0000 helpdesk@reportlinker.com Copyright 2013, Reportlinker Zend_Feed en-us http://blogs.law.harvard.edu/tech/rss http://www.reportlinker.com/d014191672/Company-Report-Biopharmaceutical-in-The-United-States-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d014191672/Company-Report-Biopharmaceutical-in-The-United-States-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ]]> Thu, 28 Feb 2013 23:00:00 +0000 http://www.reportlinker.com/d014231215/Company-Report-Vaccine-in-Canada-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d014231215/Company-Report-Vaccine-in-Canada-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ]]> Thu, 31 Jan 2013 23:00:00 +0000 http://www.reportlinker.com/d014290311/New-Enterprise-Associates-Company-Report-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d014290311/New-Enterprise-Associates-Company-Report-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ]]> Sun, 31 Mar 2013 22:00:00 +0000 http://www.reportlinker.com/d014339974/Intercell-AG-Company-Report-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d014339974/Intercell-AG-Company-Report-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... And production of rare, fully human monoclonal antibodies are offered by vivalis. Through these programs, vivalis receives payments associated with the funding of discovery research, an upfront payment, clinical ...]]> Tue, 30 Apr 2013 22:00:00 +0000 http://www.reportlinker.com/d014343124/Company-Report-Protein-in-The-United-States-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d014343124/Company-Report-Protein-in-The-United-States-for-Year-2013.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... Therapeutics for folding diseases or folding solutions are difficult to develop because proteins are moving targets }disease or misfolding n o ye s -high throughput readout signal -- yes/no decrease ...]]> Tue, 30 Apr 2013 22:00:00 +0000 http://www.reportlinker.com/d014194622/Enzyme-Sector-Analysis.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d014194622/Enzyme-Sector-Analysis.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... Production Preparation of enzymes 21/03/2013 why enzymes Catalysts increase the rate of reactions without any net change in their structure. Concept of catalysis is developed as early as the 19th ...]]> Thu, 28 Feb 2013 23:00:00 +0000 http://www.reportlinker.com/d014277010/The-Indian-Enzyme-Industry-Brief-enzyme-protein-.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d014277010/The-Indian-Enzyme-Industry-Brief-enzyme-protein-.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... Accounts for 10% of the global scenario [29]. The demand of diagnostic and therapeutic enzymes is expected to increase owing to improvement in medical care facilities in developing countries and global ...]]> Thu, 28 Feb 2013 23:00:00 +0000 http://www.reportlinker.com/d014345972/Biosimilar-Market-Analysis-in-The-United-States-and-Japan.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d014345972/Biosimilar-Market-Analysis-in-The-United-States-and-Japan.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... Be treated as a unique entity diclofenac = monoclonal antibodies shown within the circles: the reference product and each biosimilar has different post-translational modifications (in this case ...]]> Tue, 30 Apr 2013 22:00:00 +0000 http://www.reportlinker.com/d014341546/The-South-Korean-Bioprocessing-Industry-Brief-bioprocessing-biosimilar-.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d014341546/The-South-Korean-Bioprocessing-Industry-Brief-bioprocessing-biosimilar-.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... Innovation in biologics will be the theme of this meeting. Among the biologic drug cands, monoclonal antibody (mab) is the fastest growing area of global pharmaceutical market. Mab is set to lead ...]]> Sun, 31 Mar 2013 22:00:00 +0000 http://www.reportlinker.com/d014330033/U-S-Antibody-Industry-Brief.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public http://www.reportlinker.com/d014330033/U-S-Antibody-Industry-Brief.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_public ... Selection antibody generation assay development cell line development bio-analytical assay development manufacturing research process optimization product positioning research poc studies additional ...]]> Sun, 31 Mar 2013 22:00:00 +0000 http://www.reportlinker.com/p0379851/Analytical-Tool-Antibodies-and-Peptides-in-Oncology.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p0379851/Analytical-Tool-Antibodies-and-Peptides-in-Oncology.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium "Analytical Tool - Antibodies and Peptides in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in the antibody and ...]]> Sun, 21 Apr 2013 22:00:00 +0000 http://www.reportlinker.com/p01155484/Protein-Engineering-Market-Products-Monoclonal-Antibody-Insulin-Analog-Modified-EPO-Technology-Sequential-Modification-Glycosylation-PEGylation-and-Applications-Therapeutics-Diagnostics-Research-Global-Forecast-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01155484/Protein-Engineering-Market-Products-Monoclonal-Antibody-Insulin-Analog-Modified-EPO-Technology-Sequential-Modification-Glycosylation-PEGylation-and-Applications-Therapeutics-Diagnostics-Research-Global-Forecast-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Proteins exhibit high specificity and less immunogenicity and are widely used as therapeutic agents in the treatment of various disorders and diseases. There are more than 200 protein-based products currently ...]]> Wed, 27 Mar 2013 23:00:00 +0000 http://www.reportlinker.com/p0284885/Triple-Analysis-Melanoma-Cancer-Vaccines-and-Antibodies.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p0284885/Triple-Analysis-Melanoma-Cancer-Vaccines-and-Antibodies.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies). ...]]> Mon, 18 Mar 2013 23:00:00 +0000 http://www.reportlinker.com/p0284870/Triple-Analysis-Leukemia-Cancer-Vaccines-and-Antibodies.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p0284870/Triple-Analysis-Leukemia-Cancer-Vaccines-and-Antibodies.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies). ...]]> Mon, 18 Mar 2013 23:00:00 +0000 http://www.reportlinker.com/p0284881/Triple-Analysis-Lymphoma-Cancer-Vaccines-and-Antibodies.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p0284881/Triple-Analysis-Lymphoma-Cancer-Vaccines-and-Antibodies.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies). ...]]> Mon, 18 Mar 2013 23:00:00 +0000 http://www.reportlinker.com/p0284892/Triple-Analysis-Cancer-Vaccines-Protein-Kinase-Inhibitors-and-Antibodies.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p0284892/Triple-Analysis-Cancer-Vaccines-Protein-Kinase-Inhibitors-and-Antibodies.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors and by the compound strategy of Antibodies. ...]]> Mon, 18 Mar 2013 23:00:00 +0000 http://www.reportlinker.com/p0284673/Triple-Analysis-Cancer-Vaccines-Antibodies-and-Peptides.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p0284673/Triple-Analysis-Cancer-Vaccines-Antibodies-and-Peptides.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium This triple analysis focuses on cancer drug development strategies by the mechanism/target/effect of Cancer Vaccines and by the two compound strategies of Antibodies and Peptides. Each of these three individual ...]]> Mon, 18 Mar 2013 23:00:00 +0000